X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12281) 12281
type-2 diabetes-mellitus (11599) 11599
male (6879) 6879
female (6288) 6288
endocrinology & metabolism (5289) 5289
diabetes (5059) 5059
middle aged (4768) 4768
type-2 (4278) 4278
adult (3859) 3859
risk factors (3721) 3721
type 2 diabetes (3288) 3288
animals (3239) 3239
glucose (3101) 3101
obesity (3083) 3083
aged (3081) 3081
insulin resistance (2785) 2785
diabetes mellitus (2642) 2642
insulin (2608) 2608
insulin-resistance (2426) 2426
metabolic syndrome (2153) 2153
diabetes mellitus, type 2 - drug therapy (2100) 2100
risk (2090) 2090
pharmacology & pharmacy (2005) 2005
research (1837) 1837
analysis (1825) 1825
blood glucose - metabolism (1699) 1699
medicine, general & internal (1687) 1687
hypoglycemic agents - therapeutic use (1682) 1682
prevalence (1564) 1564
health aspects (1532) 1532
body mass index (1506) 1506
glycemic control (1453) 1453
hypertension (1448) 1448
cardiovascular-disease (1430) 1430
mortality (1381) 1381
cardiovascular disease (1304) 1304
medicine & public health (1294) 1294
diabetes mellitus, type 2 - blood (1269) 1269
internal medicine (1268) 1268
treatment outcome (1254) 1254
cardiac & cardiovascular systems (1252) 1252
dextrose (1220) 1220
metabolism (1203) 1203
biochemistry & molecular biology (1177) 1177
coronary-heart-disease (1155) 1155
metformin (1150) 1150
nutrition & dietetics (1150) 1150
physiological aspects (1145) 1145
oxidative stress (1143) 1143
mice (1142) 1142
mellitus (1129) 1129
inflammation (1121) 1121
care and treatment (1108) 1108
association (1101) 1101
hyperglycemia (1100) 1100
prevention (1033) 1033
studies (1030) 1030
abridged index medicus (1017) 1017
risk-factors (1017) 1017
cardiovascular diseases (1003) 1003
disease (990) 990
rats (987) 987
double-blind (983) 983
adolescent (975) 975
young adult (973) 973
medicine, research & experimental (935) 935
diet (932) 932
diabetes mellitus, type 2 - complications (927) 927
medicine (906) 906
peripheral vascular disease (904) 904
atherosclerosis (893) 893
blood-pressure (890) 890
blood pressure (889) 889
insulin - blood (864) 864
diabetes mellitus, type 2 - metabolism (862) 862
type 2 diabetes mellitus (835) 835
insulin - metabolism (834) 834
glucose metabolism (820) 820
exercise (819) 819
cholesterol (818) 818
glucagon-like peptide-1 (816) 816
cross-sectional studies (812) 812
c-reactive protein (808) 808
type-2 diabetic-patients (793) 793
diabetes mellitus, type 2 - epidemiology (772) 772
therapy (770) 770
review (766) 766
population (760) 760
glucose tolerance test (758) 758
impaired glucose-tolerance (738) 738
medical research (732) 732
hypoglycemic agents - pharmacology (729) 729
insulin sensitivity (723) 723
management (704) 704
blood glucose - analysis (703) 703
physiology (703) 703
body-mass index (697) 697
epidemiology (694) 694
research article (694) 694
prospective studies (693) 693
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18039) 18039
German (193) 193
Spanish (123) 123
Japanese (71) 71
French (44) 44
Portuguese (27) 27
Russian (26) 26
Polish (21) 21
Hungarian (10) 10
Chinese (7) 7
Italian (4) 4
Korean (4) 4
Czech (3) 3
Turkish (3) 3
Arabic (1) 1
Dutch (1) 1
Indonesian (1) 1
Norwegian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 130, Issue 18, pp. 1579 - 1588
Journal Article
Diabetologia, ISSN 1432-0428, 2015, Volume 59, Issue 1, pp. 13 - 20
Journal Article
American Family Physician, ISSN 0002-838X, 2016, Volume 93, Issue 2, pp. 103 - 109
Journal Article
by Chen, X and Wang, WJ and Li, RE and Yu, J and Gao, L
MEDICINE, ISSN 0025-7974, 11/2019, Volume 98, Issue 44, p. e17519
...) and the susceptibility to diabetes mellitus (DM), but the conclusions remain controversial. This study was to investigate the true contribution of miRNA SNPs to the risk of DM by using a meta-analysis of all the published studies. Methods... 
microRNAs | OXIDATIVE STRESS | meta-analysis | diabetes mellitus | polymorphism | VARIANT | MIR-27A | MEDICINE, GENERAL & INTERNAL | NEUROPATHY | INFLAMMATION | single nucleotide | RS2910164 | RS895819 | TYPE-2 | MIR-146A EXPRESSION | Hispanic Americans - genetics | Diabetes Mellitus - genetics | Humans | Asian Continental Ancestry Group - genetics | Diabetes Mellitus - ethnology | Genotype | MicroRNAs - genetics | Polymorphism, Single Nucleotide | Odds Ratio | Case-Control Studies | Genetic aspects | MicroRNA | Diabetes | Single nucleotide polymorphisms | Health aspects | Risk factors
Journal Article
Medicine (United States), ISSN 0025-7974, 11/2017, Volume 96, Issue 46, p. e8588
Journal Article
Journal Article
Naunyn-Schmiedeberg's archives of pharmacology, ISSN 1432-1912, 2011, Volume 385, Issue 4, pp. 423 - 436
The pharmacological profile of ipragliflozin (ASP1941; (1S)-1,5-anhydro-1-C-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-d-glucitol compound with... 
Neurosciences | Hyperglycemia | Biomedicine | Urinary glucose excretion | Diabetes | Pharmacology/Toxicology | Ipragliflozin | Sodium–glucose cotransporter 2 | Sodium-glucose cotransporter 2 | GLYCEMIC CONTROL | DAPAGLIFLOZIN | TUBULAR REABSORPTION | RATS | INSULIN | RECESSIVE RENAL GLUCOSURIA | MUTATION | PHARMACOLOGY & PHARMACY | SODIUM-GLUCOSE COTRANSPORTER | TYPE-2 DIABETES-MELLITUS | Carbohydrate Metabolism - drug effects | Diabetes Mellitus, Experimental - drug therapy | Glucosides - blood | Cricetulus | Humans | Male | Glucosides - pharmacokinetics | Insulin - blood | Thiophenes - blood | Diabetes Mellitus, Experimental - blood | Hypoglycemic Agents - blood | CHO Cells | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Cricetinae | Glucosides - pharmacology | Hypoglycemic Agents - pharmacokinetics | Blood Glucose - analysis | Rats | Thiophenes - pharmacology | Gastrointestinal Tract - drug effects | Diabetes Mellitus, Type 2 - urine | Diabetes Mellitus, Type 1 - urine | Rats, Sprague-Dawley | Gastrointestinal Tract - metabolism | Mice, Inbred ICR | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 1 - drug therapy | Hypoglycemic Agents - pharmacology | Thiophenes - pharmacokinetics | Diabetes Mellitus, Type 2 - blood | Animals | Diabetes Mellitus, Experimental - urine | Diabetes Mellitus, Type 1 - blood | Phlorhizin - pharmacokinetics | Mice | Phlorhizin - blood | Diabetes Mellitus, Type 2 - drug therapy | Sorbitol | Type 1 diabetes | Analysis | Proline | Glucose | Glibenclamide | Dextrose
Journal Article
Diabetes care, ISSN 1935-5548, 2016, Volume 39, Issue Supplement 2, pp. S165 - S171
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing... 
GLUCOSE COTRANSPORTER 2 | DAPAGLIFLOZIN | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | RENAL-DISEASE | GLOMERULAR HYPERFILTRATION | TYPE-2 | NEPHROPATHY | BLOOD-PRESSURE | EMPAGLIFLOZIN | Albuminuria - complications | Cardiovascular Diseases - prevention & control | Humans | Kidney Glomerulus - physiopathology | Diabetes Mellitus, Type 1 - complications | Glomerular Filtration Rate - physiology | Albuminuria - physiopathology | Glomerular Filtration Rate - drug effects | Diabetic Nephropathies - physiopathology | Glucosides - therapeutic use | Blood Pressure - drug effects | Blood Pressure - physiology | Benzhydryl Compounds - therapeutic use | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Kidney - physiopathology | Hypoglycemic Agents - therapeutic use | Kidney Failure, Chronic - physiopathology | Kidney - drug effects | Cardiovascular Diseases - metabolism | Diabetes Mellitus, Type 1 - physiopathology | Kidney Failure, Chronic - drug therapy | Kidney Glomerulus - drug effects | Risk Factors | Sodium-Glucose Transporter 2 Inhibitors | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - physiopathology | Albuminuria - drug therapy | Diabetes Mellitus, Type 1 - blood | Kidney Failure, Chronic - complications | Renin-Angiotensin System - drug effects | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 2019, Volume 18, Issue 1, pp. 20 - 14
Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D).... 
CARDIAC & CARDIOVASCULAR SYSTEMS | Hypoglycemic therapy | ADD-ON | GLUCOSE COTRANSPORTER | COMBINATION THERAPY | COTRANSPORTER 2 INHIBITION | GLUCAGON-LIKE PEPTIDE-1 | IMPROVES GLYCEMIC CONTROL | ENTEROENDOCRINE CELLS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | CARDIOVASCULAR-DISEASE | Diabetes | TYPE-2 DIABETES-MELLITUS | SGLT2 inhibitors | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 - drug effects | Kidney - drug effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Sodium-Glucose Transporter 2 - metabolism | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Treatment Outcome | Biomarkers - blood | Diabetes Mellitus, Type 1 - drug therapy | Blood Glucose - drug effects | Diabetes Mellitus, Type 1 - diagnosis | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Kidney - metabolism | Animals | Diabetes Mellitus, Type 1 - blood | Glycosides - adverse effects | Sodium-Glucose Transporter 1 - metabolism | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Glycosides - therapeutic use | Glucose transporter | Urine | Medical research | Excretion | Kidneys | Peptides | Diabetes mellitus | Clinical trials | Systematic review | Diabetes mellitus (insulin dependent) | Glucose | Insulin | Small intestine | Optimization | Infusion | Inhibitors | Sodium | Intestine | Hemoglobin | Blood pressure | Adults | Diabetes mellitus (non-insulin dependent) | Transporter
Journal Article